Jeegar Patel

Dr. Jeegar Patel has served as chief scientific officer since October 2022. Prior to Evommune, Dr. Patel served as senior vice president, research and nonclinical development at Kadmon Holdings, Inc., a Sanofi Company, where he held positions of increasing responsibility and led the research and development organization with a therapeutic focus in fibrosis, immunology and immuno-oncology. He has directly contributed to multiple IND and NDA filings across therapeutic areas, including the development and approval of Rezurock® (FDA Approved July 2021) which led to Sanofi’s $1.9 billion acquisition of Kadmon in late 2021, with Dr. Patel leading Kadmon's R&D activity integration into Sanofi. Prior to joining Kadmon, Dr. Patel was a nonclinical development project leader at ImClone Systems (Acquired by Eli Lilly in 2008) and led nonclinical development activities resulting in the approval of Cyramza® (aVEGFR2 Mab), Portrazza® (aEGFR Mab), and Lartruvo® (aPDGFb Mab). Dr. Patel began his career as a nonclinical development project toxicologist at Abbott Laboratories and Hoechst Marion Roussel. Dr. Patel received his Bachelor of Science (BS) in Pharmacology and Toxicology from the University of the Sciences in Philadelphia and his Doctorate in Pharmacology and Physiology (PhD) from Drexel University, College of Medicine.